loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Acutaas Chemicals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Acutaas Chemicals Ltd. 17 Oct 2025 12:41 PM
Result PDF

Q2FY26 Quarterly Result Announced for Acutaas Chemicals Ltd.

Pharmaceuticals company Acutaas Chemicals announced Q2FY26 results

  • Revenue from operations for Q2FY26 grew by 24.1% YoY to Rs 3,062 million.
  • The gross margin for the quarter improved to 55.8% up 1,232 bps YoY.
  • EBITDA for the quarter came at Rs 953 million up 94.8% YoY.
  • EBITDA margin for the quarter was at 31.1% as compared to 19.8% in Q2FY25.
  • PAT for the quarter was Rs 719 million up 91.3% as compared to PAT of Rs 376 million in Q2FY25.
  • The PAT margin for the quarter was at 23.5% up 824 bps YoY.
  • Export for the quarter at 76%; domestic business at 24%.

Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals, said: “Our focus has always been on building a long-term, sustainable business rather than chasing short-term opportunities. This disciplined approach is now yielding tangible results as we strengthen global partnerships and expand into new growth verticals such as Battery Chemicals and Semiconductors.

In Q2FY26, our revenue grew by 24.1% YoY to Rs 3,062 million, driven by strong performance in Advanced Pharmaceutical Intermediates and stable contributions from Specialty Chemicals.

We remain confident of delivering around 25% revenue growth for the full year, backed by a resilient business foundation and clear strategic direction”

Result PDF

Result PDF

Pharmaceuticals company Acutaas Chemicals announced Q1FY26 results

  • Revenue from operations for Q1FY26 grew by 17.3% YoY to Rs 2,072 million
  • The gross margin for the quarter improved to 53.2% up 1,117 bps YoY
  • EBITDA for the quarter came at Rs 509 million up 72.4% YoY
  • EBITDA margin for the quarter was at 24.6% as compared to 16.7% in Q1FY25
  • PAT for the quarter was Rs 440 million up 199.6% as compared to PAT of Rs 147 million in Q1FY25
  • The PAT margin for the quarter was at 21.2% up 1,292 bps YoY
  • Export for the quarter at 60%; domestic business at 40%

Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am happy to share that we’ve had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality.

I am happy to announce that we have entered into a joint venture in South Korea which brings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space. With rising customer engagement across COMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins.”

Result PDF

Pharmaceuticals company Ami Organics announced Q4FY25 results

  • Revenue from operations for Q4FY25 grew by 37.1% YoY to Rs 3,085 million.
  • The gross margin for the quarter improved to 47.3% up 734 bps YoY and 108 bps QoQ.
  • EBITDA for the quarter came at Rs 850 million up 96.8% YoY compared to Rs 432 million in Q4FY24.
  • EBITDA margin for the quarter was at 27.5% as compared to 19.2% in Q4FY24.
  • PAT for the quarter was Rs 627 million up 144.2% as compared to PAT of Rs 257 million in Q4FY24.
  • The PAT margin for the quarter was at 20.3% up 892 bps YoY and 380 bps QoQ.
  • Export for the quarter at 74%; domestic business at 26%.

Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed Rs 1,000 crore in revenue a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions.

As we embark on an exciting new phase of growth, we are embracing a bold, future-focused brand identity that aligns with our vision to lead as a diversified specialty chemicals company, serving next-generation industries with a steadfast commitment to sustainability. To reflect this ambition, we are transitioning from “Ami Organics Limited” to “Acutaas Chemicals Limited”.

Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth.”

Result PDF

Pharmaceuticals company Ami Organics announced Q3FY25 results

  • Revenue from operations for Q3FY25 grew by 65.2% YoY to Rs 2,750 million.
  • The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ.
  • EBITDA for the quarter came at Rs 687 million up 159.0% YoY compared to Rs 265 million in Q3FY24.
  • EBITDA margin for the quarter was at 25.0% as compared to 15.9% in Q3FY24.
  • PAT for the quarter was Rs 454 million up 155.1% as compared to PAT of Rs 178 million in Q3FY24.
  • The PAT margin for the quarter was at 16.5% up 582 bps YoY and 130 bps QoQ.
  • Export for the quarter at 76%; domestic business at 24%.

Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am delighted to share that in the first nine months of FY25, we achieved revenue of X698 crore, nearly equalling the revenue from operations of the entire previous financial year. In Q3FY25 alone, we delivered an impressive 65.2% YoY growth, achieving Rs 275 crore in revenue from operations. This performance was driven by a strong ramp-up in our CDMO business and consistent growth in advanced pharmaceutical intermediates.

Our pipeline of CDMO projects is progressing well, with several initiatives nearing commercialization by FY26, solidifying the foundation for sustained long-term growth. Ongoing discussions with innovators and partners remain highly encouraging, and we are confident that the CDMO segment will see exponential growth in the coming years.

With improved visibility for Q4, | am pleased to revise our FY25 growth guidance upward from 30% to 35%. This milestone reflects our unwavering commitment to delivering consistent progress, embracing adaptability, and seizing new opportunities that ensure sustainable and impactful growth.”

Result PDF

Pharmaceuticals company Ami Organics announced Q2FY25 results

  • Revenue from operations for Q2FY25 grew by 43.2% YoY to Rs 2,467 million.
  • The gross margin for the quarter improved to 43.4% up 239 bps YoY and 136 bps QoQ
  • EBITDA for the quarter came at Rs 489 million up 97.2% YoY compared to Rs 248 million in Q2FY24.
  • EBITDA margin for the quarter was at 19.8% as compared to 14.4% in Q2FY24.
  • PAT for the quarter was Rs 375 million up 155% as compared to adjusted PAT of Rs 147 million in Q2FY24.
  • The PAT margin for the quarter was at 15.2% up 668 bps YoY and 682 bps QoQ.
  • Export at 76%; domestic business at 24%.
  • Further to the inspection concluded by by Pharmaceutical and Medical Devices Agency, Japan (“PMDA”) without any critical/major observation, the agency has issued Inspection Result Report declaring the Sachin Facility as a Good Manufacturing Practices (GMP) compliant.

Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “Despite ongoing challenges in the global chemical industry, I am pleased to report stellar year-over-year growth of 43.2% in Q2FY25, driven by exceptional performance in our Pharmaceutical Intermediates and Specialty Chemicals businesses. Our key products maintained growth momentum, and an earlier-than-anticipated ramp-up in our CDMO business provided an additional boost to our results.

I am also proud to announce that PMDA Japan has issued an Inspection Result Report declaring our Sachin Facility as Good Manufacturing Practices (GMP) compliant.

We are experiencing a resurgence in demand for our core molecules, bolstered by ramp up in CDMO contract and strong volume growth within our Specialty Chemicals division. Based on the current order pipeline, we are raising our revenue growth guidance for FY25 from 25% to 30%.”

Result PDF

Pharmaceuticals company Ami Organics announced Q1FY25 results:

  • Revenue from operations for Q1FY25 grew by 14.9% YoY to Rs 1,767 million
  • The gross margin for the quarter was at 42.1%. 
  • EBITDA for the quarter came at Rs 295 million down 13.2% YoY compared to Rs 340 million in Q1FY24.
  • EBITDA margin for the quarter was at 16.7% as compared to 22.1% in Q1FY24. EBITDA margins contracted due to lower gross margins coupled with higher employee expenses led by annual increments as well as new hiring for Ankleshwar plant.
  • PAT for the quarter was Rs 147 million. PAT margin for the quarter was 8.3%. PAT margins were impacted due to higher finance cost as well as higher depreciation cost.

Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am pleased to report that we continue to successfully navigate the challenging industry landscape, achieving strong revenue of ?176 crore, which represents a 14.9% year-over-year growth. This growth was primarily driven by our core pharmaceutical business, while the specialty chemicals segment saw a modest 10% increase.

During the quarter, we also successfully completed the Good Manufacturing Practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan, with no critical or major observations. To our knowledge, we may be the only company in India to have successfully passed both USFDA and PMDA inspections in the advanced pharmaceutical intermediate sector.

Historically, Q1 is always lowest quarter in terms of revenue each financial year since inception, and we typically see sequential growth from Q1 to Q4. I anticipate similar strong sequential growth in the coming quarters. Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year.”

Result PDF

Pharmaceuticals company Ami Organics announced Q4FY24 & FY24 results:

  • Revenue from operations for Q4FY24 grew by 20.7% YoY and 35.2% QoQ to Rs 2,250 million
  • The gross margin for the quarter was at 40.0%. Gross margins were impacted due to change in product mix.
  • EBITDA for the quarter came at Rs 432 million up 5.9% YoY compared to Rs 408 million in Q4FY23 and up 62.8% QoQ compared to Rs 265 million in Q3FY24.
  • EBITDA margin for the quarter was at 19.2% as compared to 21.9% in Q4FY23 and 15.9% in Q3FY24. EBITDA margins contracted by 269bps YoY and grew by 326 bps sequentially.
  • Adjusted PAT for the quarter was Rs 260 million. Adjusted PAT margin for the quarter was 11.6%.

Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am pleased to share that we have been successful in navigating through the tough industry scenario to deliver an all-time high quarterly revenue from operations of Rs 225 crore. This represents a growth of 21% YoY and an exceptional 35% sequential growth. Our advanced pharmaceuticals business, grew strongly by 18% YoY and 47% QoQ while our specialty chemicals business grew robustly by 36% YoY during the quarter.

I am delighted to share that we have achieved the 'Gold Medal' accreditation from EcoVadis. Although we are in chemicals manufacturing industry, we remain steadfast on our sustainability goals propelled by an intensified focus on green chemistry and green initiatives. This commitment underscores our proactive approach to environmental responsibility and sustainability.

I am also thrilled to inform you that recently we have received grant of 3 process patents from The Patent Office, Government of India. Two of these three products are niche and complex in nature.

Overall, I believe that we have navigated industry challenges adeptly in FY24 and as we progress ahead with improved overall prospects for the industry, we firmly believe we will sustain our growth trajectory, targeting a revenue growth in range of 20-25% for the fiscal year FY25.”

Result PDF

Pharmaceutical company Ami Organics announced Q3FY24 results:

Financial Highlights for Q3FY24:

  • Revenue from operations for Q3FY24 grew by 9.2% YoY to Rs 1,664 million. The gross margin for the quarter was at 42.9% as compared to 46% in Q3FY23 and 41% in Q2FY24. Gross margins contracted 303 basis points YoY but expanded by 190 bps sequentially. Gross margins were driven by unfavourable product mix and pricing pressure.
  • EBITDA for the quarter came at Rs 265 million, down 13.9% YoY compared to Rs 308 million in Q3FY23 and up 6.8% QoQ compared to Rs 248 million in Q2FY24.
  • EBITDA margin for the quarter was at 15.9% as compared to 20.2% in Q3FY23 and 14.4% in Q2FY24. EBITDA margins degrew by 430bps YoY and grew by 153 bps sequentially. EBITDA margins were largely driven by gross margins.
  • PAT for the quarter was Rs 178 million. The PAT margin for the quarter was 10.7%

Commenting on the results, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said, “In the face of a challenging landscape of the chemical industry, I am pleased to report that we have been able to deliver quality growth in Q3FY23 with our revenue from operations growing 9.2% YoY to Rs. 1,664million. This growth is underpinned by robust volume growth of 25%, indicating strong business traction.

During the quarter, we further solidified our relationship with Fermion by signing an agreement for two additional advanced intermediates for their APIs. This milestone reflects AMI Organics’ prowess in fostering enduring client relationships, ably supported by strong R&D and manufacturing strengths. Additionally, we also inaugurated a state-of-the-art, technology-driven plant at our Ankleshwar site, designed to meet the growing demand in the pharmaceutical intermediate business. I am also excited to share that we have signed an MOU with a global manufacturer of electrolytes for the manufacturing of electrolytes for battery cells and allied materials. In this context, we have also signed an MoU with the Government of Gujarat for investment amounting up to Rs 300 crores for setting up of a dedicated manufacturing facility for electrolytes business in Gujarat.

Despite the industry headwinds, we remain confident of closing the year with healthy growth. I would also like to highlight that the various initiatives we have taken in FY23 and FY24 enhances our revenue visibility for FY25 and beyond, bolstering our confidence in our potential for stronger growth in coming years.”

 

 

Result PDF

Pharmaceuticals company Ami Organics announced Q2FY24 results:

  • Revenue from operations for Q2FY24 grew by 17.3% YoY to Rs 1,724 million
  • The Gross margin for Q2FY24 was at 41% as compared to 48% in Q2FY23. Lower gross margins were on account of high price erosion and higher sales of low-margin products
  • EBITDA for Q2FY24 came at Rs 248 million down 11.8% YoY compared to Rs 281 million in Q2FY23
  • EBITDA margin for Q2FY24 was at 14.4% as compared to 19.1% in Q2FY23, the drop of 470bps was on account of gross margins as well as higher employee cost, which was driven by annual increments, ESOP, and hiring for the Ankleshwar unit
  • Adjusted PAT for Q2FY24 was Rs 147 million, down 22.6% YoY as compared to Q2FY23.
  • Export at 54%; domestic business at 46%

Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said, “I am pleased to report a 17% YoY growth, with revenue from operations of Rs 172 crore for Q2FY24, despite facing downward pricing pressures. Even as we navigated the low-demand landscape and delivered growth, our margins took a hit this quarter driven by high pricing pressure and higher sales of low-margin products. Still, our strong order book points to a robust second half of FY24.

On the business front, Advance Pharmaceutical business delivered steady growth of ~8% YoY, even as a global customer delayed the launch in certain markets impacting our growth for Q2FY24. Further extending our relationship with Fermion, we have signed one more contract for Advanced Intermediates for their product taking total products under the CDMO contract to 3, enhancing revenue visibility for the coming years.

On the specialty chemicals side, we delivered strong 72% growth YoY, driven by robust volume. The launch of a new UV Observer product is set to enhance our portfolio, contributing to our financials from Q3FY24.

In our commitment towards sustainability and operational cost reduction, the board has approved investment in a 16 MW solar power plant which along with an already work-in-progress 5 MW solar power plant will nullify our electricity expense once fully operational.

Deferment in product launch in certain markets by a global customer coupled with pricing pressure due to oversupply from China is expected to have some impact on the numbers and even though we are expecting to deliver robust H2FY24, overall, we are modifying our growth target from 22-25% for the full year to 18-22% growth for FY24.”

 

Result PDF

Pharmaceuticals company Ami Organics announced Q1FY24 results:

  • Revenue from operations for Q1FY24 grew by 8.7% YoY to Rs 1,424 million
  • The Gross margin for Q1FY24 was at 44.8% as compared to 48.8% in Q1FY23. The lower gross margin for Q1FY24 was due to the product mix.
  • EBITDA for Q1FY24 came at Rs 252 million up 9.7% YoY compared to Rs 229 million in Q1FY23.
  • EBITDA margin for Q1FY24 was at 17.7% as compared to 17.5% in Q1FY23. EBITDA margin for Q1FY24 was suppressed on account of higher employee costs.
  • PBT for Q1FY24 was at Rs 223 million up 9.8% YoY as compared to Q1FY23
  • PAT for Q1FY24 was at Rs 167 million up 12% YoY as compared to Q1FY23
  • PAT margin for Q1FY24 was at 11.7% as compared to 11.3% in Q1FY23

Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said, “I am extremely pleased that we have been able to deliver sustained growth during the quarter, on the back of deflationary pricing environment in the chemicals industry. Our revenue from operations grew by 9% to Rs 142 crore. The growth was driven by strong momentum in the specialty chemicals business with a steady trajectory in the advanced pharmaceutical intermediate business.

Segment-wise, I believe advanced intermediate business will recover strongly from Q2FY24 onwards whereas we will be commercialising a new product during Q2FY24 in the specialty chemicals segment which will further boost the growth for the segment.

In the electrolyte business, we are very close to signing contracts with a few customers, and details of the same will be shared once we sign the MOU. I would like to mention, the size of these contracts that we are discussing with customers is much larger than what we had anticipated.

Overall, I believe despite the challenging external environment, we are confident of delivering strong growth with robust margins during the year.”

 

 

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status